HER2-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab Regimens.
Enora LaasArnaud BressetJean-Guillaume FéronClaire Le GalLauren DarriguesFlorence CoussyBeatriz GrandalLucie LaotJean-Yves PiergaFabien ReyalAnne Sophie HamyPublished in: Cancers (2021)
In patients with HER2-positive BC, the NAC strategy is more beneficial than the AC strategy, particularly in cN-positive and postmenopausal patients. NAC should be used as a first-line treatment for HER2-positive tumors.
Keyphrases
- positive breast cancer
- end stage renal disease
- lymph node
- transcription factor
- ejection fraction
- newly diagnosed
- chronic kidney disease
- rectal cancer
- peritoneal dialysis
- prognostic factors
- neoadjuvant chemotherapy
- squamous cell carcinoma
- epidermal growth factor receptor
- locally advanced
- sentinel lymph node
- ultrasound guided
- combination therapy
- replacement therapy